Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients, where it helps reduce elevated blood pressure by causing vasodilation of peripheral arteries.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide in accordance with EU quality standards. Our global logistics network ensures timely delivery and regulatory compliance across multiple regions.

Lacidipine is a calcium channel blocker used to treat conditions related to high blood pressure. - Essential hypertension: lowers systolic and diastolic pressure in adults with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure in older patients. - Hypertension with cardiovascular disease: assists in blood pressure control as part of combination therapy.

Lacidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Nausea: mild stomach discomfort or urge to vomit. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of the face, lips, tongue, or throat requiring emergency care. - Myocardial infarction: rare occurrence of heart attack. - Significant liver enzyme elevation: abnormal liver function tests. - Life‑threatening allergic reactions: anaphylaxis or severe rash.

Before initiating therapy, certain precautions should be considered. - Blood pressure monitoring: regularly assess to ensure therapeutic response. - Liver function assessment: evaluate hepatic status, especially in patients with known liver disease. - Elderly patients: start at the lowest effective dose and monitor for hypotension. - Concomitant antihypertensives: adjust doses to avoid excessive blood pressure lowering. - Heart failure: use with caution and monitor for worsening symptoms. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels. - Grapefruit juice: can elevate drug concentration and risk of hypotension. - Co‑administration with other potent vasodilators: may cause severe blood pressure drops.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacidipine effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal impairment. - Diuretics: may enhance the hypotensive effect and require dose adjustments.